Psoriasis News and Research

Latest Psoriasis News and Research

FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the U.S. Food & Drug Administration (FDA) has cleared the Company to proceed with the proposed Phase 2 trial of PrevOnco™, its proprietary cancer treatment for patients with advanced, unresectable hepatocellular carcinoma (HCC), or liver cancer. The FDA granted PrevOnco™ orphan drug status in August 2008, and in March 2010, NexMed filed its Investigational New Drug (IND) application for the product candidate.

27 Apr 2010

Anacor Pharmaceuticals, MMV partner to discover and develop promising new malaria therapeutics

Anacor Pharmaceuticals today announced that it has entered into a research agreement with not-for-profit Medicines for Malaria Venture (MMV) to explore Anacor's novel boron chemistry platform for developing new therapeutics for the treatment of malaria. Under the agreement, Anacor will be responsible for leading the research effort and MMV will contribute its extensive malaria drug research expertise as well as financial support.

26 Apr 2010

Johnson & Johnson' first-quarter 2010 sales increase 4.0% to $15.6 billion

Johnson & Johnson today announced sales of $15.6 billion for the first quarter of 2010, an increase of 4.0% as compared to the first quarter of 2009. Operational results declined 0.1% and the positive impact of currency was 4.1%.

21 Apr 2010

Study underscores potential for VBL Therapeutics VB-111 as broad-spectrum cancer therapy

VBL Therapeutics today announced positive results from preclinical and Phase 1 studies evaluating the company's lead anti-cancer agent, VB-111 - a first-in-class, targeted biological agent shown to work via dual-action, anti-angiogenic and vascular disruptive mechanism of action - in metastatic cancer. Preclinical data evaluating VB-111 in a comprehensive set of in vivo studies employing the Lewis Lung metastasis mouse model showed the compound to be safe and specific, with a 90% reduction in tumor burden of lung metastases after only one injection.

20 Apr 2010

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Findings published today in The New England Journal of Medicine from a first-of-its-kind comparator trial evaluating the anti-tumor necrosis factor (TNF)-alpha biologic treatment REMICADE (infliximab) in the treatment of moderately to severely active Crohn's disease in patients who were naive to immunomodulator and biologic therapy, showed that a significantly greater proportion of patients receiving REMICADE achieved steroid-free remission and mucosal healing compared with patients receiving azathioprine.

16 Apr 2010

New research identifies cellular channel that regulates skin and hair growth

Skin and hair follicles are constantly renewed in the body, maintained by specialized stem cells. New research from Children's Hospital Boston identifies a small cellular channel that regulates skin and hair growth and that could be targeted with small-molecule drugs, potentially treating variety of skin conditions, as well as thinning hair or unwanted hair growth. Findings appear in the April 16, 2010 issue of Cell.

16 Apr 2010

VBL Therapeutics announces upcoming presentations at premier dermatology and cancer research meetings

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immuno-inflammatory diseases and cancer, today announced the upcoming presentations of clinical data from the company's two lead programs, VB-201 and VB-111, at premier dermatology and cancer research medical meetings this spring.

13 Apr 2010

NexMed expands San Diego facilities to accommodate pre-clinical research services

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that it has expanded its San Diego facilities to accommodate an increase in demand for its pre-clinical research services.

9 Apr 2010

Mayo Clinic Health Letter: UV light slows skin cell overgrowth, alters immune system

Ultraviolet light -- a culprit behind sunburns, wrinkles and skin cancer -- offers benefits for some skin conditions, according to the April issue of Mayo Clinic Health Letter.

9 Apr 2010

ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor

ChemoCentryx, Inc., today announced that it has identified a novel drug candidate targeting the chemoattractant receptor known as ChemR23. This investigational new drug, designated CCX832, is an orally-administered small molecule antagonist of ChemR23, an important player in inflammatory disease.

9 Apr 2010

ADDF grants Signum Biosciences $270,000 for evaluating PP2A-modulatory compounds as AD therapeutics

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it is providing a grant of $270,000 to Signum Biosciences, Inc. (Princeton, NJ) to evaluate small-molecule, orally delivered Protein Phosphatase 2a (PP2A)-modulatory compounds as disease-modifying therapeutics for Alzheimer's disease.

1 Apr 2010

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.

31 Mar 2010

New home health provisions proposed in Health Care Reform Bill to benefit older patients

New home health provisions proposed in the Health Care Reform Bill (H.R. 3590 Patient Protection and Affordable Care Act) will support the testing and implementation of in-home health care services for chronically ill elderly residents of Greater Philadelphia.

30 Mar 2010

LeAnn Rimes encourages psoriasis patients to take Make a Change Pledge

Grammy Award-winning multi-platinum recording artist and psoriasis patient LeAnn Rimes is calling for people with psoriasis to pledge to better manage their disease as part of the awareness campaign "Stop Hiding from Psoriasis." In partnership with the American Academy of Dermatology and National Psoriasis Foundation, LeAnn is encouraging people to take a stand against psoriasis by taking the Make a Change Pledge online at StopHiding.org.

30 Mar 2010

NexMed files IND with FDA for Phase II trial of PrevOnco for HCC

NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.

29 Mar 2010

SMARTube technology helps physicians create index to get accurate picture of HIV infection

New data presented at the Center for Disease Control -sponsored 2010 HIV Diagnostics Conference suggests that an assay based on SMARTube™ technology may prove useful in developing a standardized measure for estimating what proportion of those infected with HIV have become recently infected.

29 Mar 2010

FDA approves Graceway Pharmaceuticals' NDA for Zyclara

Graceway® Pharmaceuticals announced today that the Food and Drug Administration has approved the New Drug Application for Zyclara™, determining it to be safe and effective for the treatment of clinically typical, visible or palpable actinic keratoses.

27 Mar 2010

Isotechnika Pharma releases fourth quarter financial results; reviews operational and scientific highlights for 2009

Isotechnika Pharma Inc. has released its financial results for the fourth quarter and year ended December 31, 2009 and provided a review of the Company's operational and scientific highlights for 2009

25 Mar 2010

Abbott/Eisai's Humira termed as most efficacious therapy for psoriasis

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed dermatologists view Abbott/Eisai's Humira as the most efficacious therapy for the treatment of moderate to severe psoriasis. Thirty-two percent of surveyed dermatologists selected Humira as the most efficacious, followed by Centocor Ortho Biotech/Merck/Mitsubishi Tanabe's Remicade. The current sales leader Amgen/Pfizer/Takeda's Enbrel was selected as the most efficacious therapy by only 23 percent of dermatologists surveyed.

24 Mar 2010

Garnet BioTherapeutics commences treatment in GBT009 trial for incisional wounds following breast reconstruction surgery

Garnet BioTherapeutics, Inc., a regenerative medicine company focused on developing cell based therapies, today announced that the first patient has been treated in a Phase 2 multicenter, double-blind, placebo-controlled study of its lead product candidate GBT009 at Unity Hospital in Rochester, New York. GBT009 gives off a variety of pro-regenerative growth factors and cytokines which help repair damaged tissue and reduce inflammation, ultimately augmenting the body's ability to heal itself.

23 Mar 2010

Psoriasis News and Research

Latest Psoriasis News and Research

FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco

Anacor Pharmaceuticals, MMV partner to discover and develop promising new malaria therapeutics

Johnson & Johnson' first-quarter 2010 sales increase 4.0% to $15.6 billion

Study underscores potential for VBL Therapeutics VB-111 as broad-spectrum cancer therapy

Results of study comparing REMICADE to azathioprine for Crohn's disease published

New research identifies cellular channel that regulates skin and hair growth

VBL Therapeutics announces upcoming presentations at premier dermatology and cancer research meetings

NexMed expands San Diego facilities to accommodate pre-clinical research services

Mayo Clinic Health Letter: UV light slows skin cell overgrowth, alters immune system

ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor

ADDF grants Signum Biosciences $270,000 for evaluating PP2A-modulatory compounds as AD therapeutics

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

New home health provisions proposed in Health Care Reform Bill to benefit older patients

LeAnn Rimes encourages psoriasis patients to take Make a Change Pledge

NexMed files IND with FDA for Phase II trial of PrevOnco for HCC

SMARTube technology helps physicians create index to get accurate picture of HIV infection

FDA approves Graceway Pharmaceuticals' NDA for Zyclara

Isotechnika Pharma releases fourth quarter financial results; reviews operational and scientific highlights for 2009

Abbott/Eisai's Humira termed as most efficacious therapy for psoriasis

Garnet BioTherapeutics commences treatment in GBT009 trial for incisional wounds following breast reconstruction surgery

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Psoriasis News and Research

Latest Psoriasis News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in